[HTML][HTML] HIV protease resistance mutations in patients receiving second-line antiretroviral therapy in Libreville, Gabon
GF Nzengui-Nzengui, G Mourembou… - BMC Infectious …, 2024 - Springer
Introduction In 2022, the WHO reported that 29.8 million people around the world were living
with HIV (PLHIV) and receiving antiretroviral treatment (ART), including 25 375 people in …
with HIV (PLHIV) and receiving antiretroviral treatment (ART), including 25 375 people in …
[HTML][HTML] HIV protease resistance mutations in patients receiving second-line antiretroviral therapy in Libreville, Gabon
GF Nzengui-Nzengui… - BMC Infectious …, 2024 - bmcinfectdis.biomedcentral.com
In 2022, the WHO reported that 29.8 million people around the world were living with HIV
(PLHIV) and receiving antiretroviral treatment (ART), including 25 375 people in Gabon …
(PLHIV) and receiving antiretroviral treatment (ART), including 25 375 people in Gabon …
HIV protease resistance mutations in patients receiving second-line antiretroviral therapy in Libreville, Gabon
GF Nzengui-Nzengui, G Mourembou… - BMC infectious …, 2024 - pubmed.ncbi.nlm.nih.gov
Introduction In 2022, the WHO reported that 29.8 million people around the world were living
with HIV (PLHIV) and receiving antiretroviral treatment (ART), including 25 375 people in …
with HIV (PLHIV) and receiving antiretroviral treatment (ART), including 25 375 people in …
HIV protease resistance mutations in patients receiving second-line antiretroviral therapy in Libreville, Gabon.
GF Nzengui-Nzengui, G Mourembou… - BMC Infectious …, 2024 - europepmc.org
Results Of 84 HIV plasma samples collected from 45 men and 39 women, 342 mutations
were detected. Of these, 43.3%(148/342) were associated with nucleoside reverse …
were detected. Of these, 43.3%(148/342) were associated with nucleoside reverse …
HIV protease resistance mutations in patients receiving second-line antiretroviral therapy in Libreville, Gabon.
GF Nzengui-Nzengui, G Mourembou… - BMC Infectious …, 2024 - search.ebscohost.com
Introduction: In 2022, the WHO reported that 29.8 million people around the world were
living with HIV (PLHIV) and receiving antiretroviral treatment (ART), including 25 375 people …
living with HIV (PLHIV) and receiving antiretroviral treatment (ART), including 25 375 people …
[HTML][HTML] HIV protease resistance mutations in patients receiving second-line antiretroviral therapy in Libreville, Gabon
GF Nzengui-Nzengui, G Mourembou… - BMC Infectious …, 2024 - ncbi.nlm.nih.gov
Results Of 84 HIV plasma samples collected from 45 men and 39 women, 342 mutations
were detected. Of these, 43.3%(148/342) were associated with nucleoside reverse …
were detected. Of these, 43.3%(148/342) were associated with nucleoside reverse …
[PDF][PDF] HIV protease resistance mutations in patients receiving second-line antiretroviral therapy in Libreville, Gabon
GF Nzengui-Nzengui, G Mourembou… - 2024 - bmcinfectdis.biomedcentral.com
Introduction In 2022, the WHO reported that 29.8 million people around the world were living
with HIV (PLHIV) and receiving antiretroviral treatment (ART), including 25 375 people in …
with HIV (PLHIV) and receiving antiretroviral treatment (ART), including 25 375 people in …
HIV protease resistance mutations in patients receiving second-line antiretroviral therapy in Libreville, Gabon.
GF Nzengui-Nzengui, G Mourembou… - BMC Infectious …, 2024 - europepmc.org
Results Of 84 HIV plasma samples collected from 45 men and 39 women, 342 mutations
were detected. Of these, 43.3%(148/342) were associated with nucleoside reverse …
were detected. Of these, 43.3%(148/342) were associated with nucleoside reverse …